SBWire

The Public Health Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter public health partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The Hematology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the hematology partnering deals and agreements entered into by the worlds leading healthcare companies.

The Bipolar Disorder Partnering 2009-2014 provides understanding and access to the bipolar disorder partnering deals and agreements entered into by the worlds leading healthcare companies.

The Human Papilloma Virus Partnering 2009-2014 report provides understanding and access to the human papilloma virus partnering deals and agreements entered into by the worlds leading healthcare companies.

The Diabetes Partnering 2009-2014 provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.

The Attention Deficit Disorder Partnering 2009-2014 provides understanding and access to the attention deficit disorder partnering deals and agreements entered into by the worlds leading healthcare companies.

The Respiratory Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the respiratory partnering deals and agreements entered into by the worlds leading healthcare companies.

The Lung Cancer Partnering 2009-2014 provides understanding and access to the lung cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The Common Cold Partnering 2009-2014 provides understanding and access to the common cold partnering deals and agreements entered into by the worlds leading healthcare companies.

The Infertility Partnering 2009-2014 report provides understanding and access to the infertility partnering deals and agreements entered into by the worlds leading healthcare companies.

The Anemia Partnering 2009-2014 provides understanding and access to the anemia partnering deals and agreements entered into by the worlds leading healthcare companies.

The Anthrax Partnering 2009-2014 provides understanding and access to the anthrax partnering deals and agreements entered into by the worlds leading healthcare companies.

The Crohn's Disease Partnering 2009-2014 report provides understanding and access to the crohn's disease partnering deals and agreements entered into by the worlds leading healthcare companies.

The Allergic Rhinitis Partnering 2009-2014 report provides understanding and access to the allergic rhinitis partnering deals and agreements entered into by the worlds leading healthcare companies.

The Traumatic Brain Injury Partnering 2009-2014 provides understanding and access to the traumatic brain injury partnering deals and agreements entered into by the worlds leading healthcare companies.

The HIV Partnering 2009-2014 provides understanding and access to the HIV partnering deals and agreements entered into by the worlds leading healthcare companies.

The Learning Disability Partnering 2009-2014 report provides understanding and access to the learning disability partnering deals and agreements entered into by the worlds leading healthcare companies.

The Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the world's biopharma companies. The report provides a detailed understand and analysis of how and why companies enter manufacturing and supply deals.

The Malaria Partnering 2009-2014 provides understanding and access to the malaria partnering deals and agreements entered into by the worlds leading healthcare companies.

The Gene Therapy Partnering Agreements report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.

The Motor Neurone Disease Partnering 2009-2014 provides understanding and access to the motor neurone disease partnering deals and agreements entered into by the worlds leading healthcare companies .

Retinopathy Partnering 2009-2014 report provides understanding and access to the retinopathy partnering deals and agreements entered into by the worlds leading healthcare companies.

Wound Healing Partnering 2009-2014 report provides understanding and access to the wound healing partnering deals and agreements entered into by the worlds leading healthcare companies.

FyMed, Inc., a pharmaceutical company with specialization in innovative evidence-based approaches in drug discovery, today announced successful completion of studies for FY103B, its new and proprietary lead candidate in the non-steroidal anti-inflammatory (NSAID) category. FY103B demonstrated superior therapeutic effects in the management of acute and chronic pain and inflammation, and was found to be significantly superior to celecoxib in terms of efficacy and safety.

The 2014 Cooperative Meeting of CMSC (Consortium of Multiple Sclerosis Centers) & ACTRIMS® (Americas Committee for Treatment and Research in Multiple Sclerosis), announces continuing education credits for pharmacists at its upcoming annual meeting. The CMSC & ACTRIMS Cooperative Meeting is an annual international forum of healthcare professionals committed to improving lives of people with MS through a variety of educational strategies in comprehensive care and with a team approach.